|
¿òÆ®(umt) |
ÀÓ»ó½ÃÇè PM (Project Manager) °æ·ÂÁ÷ ä¿ë
¼¿ï ±¸·Î±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
04.30 |
|
|
ÆĶó°ïÄÁ¼³Æà |
CRM(Clinical Trials Manager)/¿Ü±¹°è Á¦¾àȸ»ç ÀÓ»ó°æ·ÂÀÚ
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
05.31 |
|
|
¾Ë¸®ÄÚÁ¦¾à(ÁÖ) |
[°æ·Â] Á¦¾à»ç ÀÓ»ó ´ã´çÀÚ ¸ðÁý
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
08.17 |
|
|
½ÎÀÌÁ¨ÄÚ¸®¾Æ(ÁÖ) |
[¿Ü±¹°è Á¦¾à] RA Assistant Manager / Manager (´ë¸®/°úÀå
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
5³â¡è |
ä¿ë½Ã |
11.24 |
|
|
(ÁÖ)½Ã¹ÍÄÚ¸®¾Æ |
½Ã¹ÍÄÚ¸®¾Æ Trainer / QOL(Quality Oversight Leadership)
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
5³â¡è |
ä¿ë½Ã |
02.07 |
|
|
¿¡´Ï±×¸¶ÄÁ¼³Æà |
RA-¿Ü±¹°è Á¦¾à»ç
¼¿ï ¼´ë¹®±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
5³â¡è |
ä¿ë½Ã |
04.27 |
|
|
À£¸¶Ä¿¹ÙÀÌ¿À |
À£¸¶Ä¿¹ÙÀÌ¿À ½Å±ÔÇ×¾ÏÁ¦ ±âÀü¿¬±¸¿ø
¼¿ï ¼ÛÆı¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
5³â¡è |
ä¿ë½Ã |
08.12 |
|
|
(ÁÖ)ÄɾîÁ¨ |
¢ßÄɾîÁ¨ - ÆéŸÀ̵å ÇÕ¼º Àü¹®°¡ ¸ðÁý
°æ±â ±ºÆ÷½Ã | ´ëÇÐ(2~3³â) ÀçÇÐ |
¿¬±¸/¿¬±¸±âȹ |
5³â¡è |
»ó½Ãä¿ë |
03.31 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Post Marketing Surveillance lead
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
5³â¡è |
ä¿ë½Ã |
04.22 |
|
|
(ÁÖ)·çÆ®·Î´Ð |
·¹ÀÌÀú ÀÇ·á±â±â ±â±¸¼³°è ¿¬±¸¿ø (CREO/Pro-E/±â°è¼³°è/¸Þ
°æ±â °í¾ç½Ã ´ö¾ç±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
5³â¡è |
ä¿ë½Ã |
08.08 |
|
|
(ÁÖ)»þÆä·Ð |
Çõ½Å½Å¾à¿¬±¸¼¾ÅÍ ¿¬±¸±âȹ ÆÀÀå
¼¿ï °³²±¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
5³â¡è |
ä¿ë½Ã |
12.06 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Clinical Project Leader
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
5³â¡è |
ä¿ë½Ã |
08.29 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Clinical Project Leader
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
09.02 |
|
|
¾Ëº¸Á¨ÄÚ¸®¾Æ |
BD In-License Specialist ä¿ë
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
5³â¡è |
ä¿ë½Ã |
01.16 |
|
|
³ª³ë¹ÙÀÌ¿À½Ã½º(ÁÖ) |
³ª³ë¹ÙÀÌ¿À½Ã½º(ÁÖ) ¹ÙÀÌ¿À½Ç ¼±ÀÓ¿¬±¸¿ø
¼¿ï ±Ýõ±¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
5³â¡è |
ä¿ë½Ã |
09.19 |
|